Wikipedia

Interleukin 2

(Redirected fromAldesleukin)

Interleukin-2(IL-2) is aninterleukin,a type ofcytokinesignaling molecule in theimmune system.It is a 15.5–16kDaprotein[5]that regulates the activities ofwhite blood cells(leukocytes, oftenlymphocytes) that are responsible for immunity. IL-2 is part of the body'snatural responsetomicrobialinfection,and in discriminating between foreign ( "non-self" ) and "self". IL-2 mediates its effects by binding toIL-2 receptors,which are expressed by lymphocytes. The major sources of IL-2 are activatedCD4+T cellsand activatedCD8+T cells.[6]Put shortly the function of IL-2 is to stimulate the growth of helper, cytotoxic and regulatory T cells.

IL2
Available structures
PDBOrtholog search:PDBeRCSB
Identifiers
AliasesIL2,IL-2, TCGF, lymphokine, interleukin 2
External IDsOMIM:147680;MGI:96548;HomoloGene:488;GeneCards:IL2;OMA:IL2 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

3558

16183

Ensembl

ENSG00000109471

ENSMUSG00000027720

UniProt

P60568

P04351

RefSeq (mRNA)

NM_000586

NM_008366

RefSeq (protein)

NP_000577

NP_032392

Location (UCSC)Chr 4: 122.45 – 122.46 MbChr 3: 37.17 – 37.18 Mb
PubMedsearch[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

IL-2 receptor

edit

IL-2 is a member of a cytokine family, each member of which has afour alpha helix bundle;the family also includesIL-4,IL-7,IL-9,IL-15andIL-21.IL-2 signals through theIL-2 receptor,a complex consisting of three chains, termed alpha (CD25), beta (CD122) andgamma(CD132). The gamma chain is shared by all family members.[6]

The IL-2 receptor (IL-2R) α subunit binds IL-2 with low affinity (Kd~ 10−8M). Interaction of IL-2 and CD25 alone does not lead to signal transduction due to its short intracellular chain but has the ability (when bound to the β and γ subunit) to increase the IL-2R affinity 100-fold.[7][5]Heterodimerization of the β and γ subunits of IL-2R is essential for signalling inT cells.[8]IL-2 can signalize either via intermediate-affinity dimeric CD122/CD132 IL-2R (Kd~ 10−9M) or high-affinity trimeric CD25/CD122/CD132 IL-2R (Kd~ 10−11M).[7]Dimeric IL-2R is expressed by memory CD8+T cells andNK cells,whereasregulatory T cellsand activated T cells express high levels of trimeric IL-2R.[5]

IL-2 signaling pathways and regulation

edit

Instructions to express proteins in response to an IL-2 signal (called IL-2 transduction) can take place via 3 differentsignaling pathways;they are: (1) theJAK-STATpathway, (2) thePI3K/Akt/mTORpathway and (3) theMAPK/ERKpathway.[5]The signalling is commenced by IL-2 binding to its receptor, following which cytoplasmatic domains ofCD122andCD132heterodimerize.This leads to the activation ofJanus kinasesJAK1andJAK3which subsequentlyphosphorylateT338on CD122. This phosphorylation recruitsSTAT transcription factors,predominantlySTAT5,which dimerize and migrate to thecell nucleuswhere they bind toDNA.[9]with an "express other proteins" signal. The proteins expressed by means of the three pathways include bcl-6 (thePI3K/Akt/mTORpathway), CD25 & prdm-1 (theJAK-STATpathway) and certain cyclins (theMAPK/ERKpathway).

Gene expression regulation for IL-2 can be on multiple levels or by different ways. One of the checkpoints (in other words one of the things which needs to be done before IL-2 is expressed) is that there must be signaling through a conjunction of a T Cell Receptor (a TCR) and an HLA-peptide complex. As a result of that conjunction a signalling pathway (signalling a cell's protein making machinery to express or 'make' IL-2), a PhosphoLipase-C (PLC) dependent pathway, is set up. PLC activates 3 major transcription factors and their pathways:NFAT,NFkBandAP-1.In addition and after costimulation from CD28 the optimal activation of expression of IL-2 and these pathways is induced. In summary therefore before a cell will make IL-2 in accordance with this pathway there have to be two reactions: TCR+HLA and protein complex on the one hand and CD28 costimulation on the other indeed mere IL-2 ligation to its receptor is too low affinity to enable pathway.

At the same timeOct-1is expressed. It helps the activation. Oct1 is expressed in T-lymphocytes andOct2is induced after cell activation.

NFAThas multiple family members, all of them are located in cytoplasm and signaling goes through calcineurin, NFAT is dephosphorylated and therefore translocated to the nucleus.

AP-1is a dimer and is composed of c-Jun and c-Fos proteins. It cooperates with other transcription factors including NFkB and Oct.

NFkBis translocated to the nucleus after costimulation through CD28. NFkB is a heterodimer and there are two binding sites on the IL-2 promoter.

Function

edit

IL-2 has essential roles in key functions of the immune system,toleranceandimmunity,primarily via its direct effects onT cells.In thethymus,where T cells mature, it preventsautoimmune diseasesby promoting thedifferentiationof certain immature T cells intoregulatory T cells,which suppress other T cells that are otherwise primed to attack normal healthy cells in the body. IL-2 enhancesactivation-induced cell death (AICD).[5]IL-2 also promotes the differentiation of T cells intoeffector T cellsand intomemory T cellswhen the initial T cell is also stimulated by anantigen,thus helping the body fight off infections.[6]Together with other polarizing cytokines, IL-2 stimulates naive CD4+T cell differentiation intoTh1andTh2lymphocytes while it impedes differentiation intoTh17and folicular Thlymphocytes.[10][11]

IL-2 increases the cell killing activity of bothnatural killer cellsandcytotoxic T cells.[11]

Its expression and secretion is tightly regulated and functions as part of both transient positive and negativefeedback loopsin mounting and dampening immune responses. Through its role in the development of T cell immunologic memory, which depends upon the expansion of the number and function of antigen-selected T cell clones, it plays a key role in enduringcell-mediated immunity.[6][12]

Evolution

edit

IL-2 has been discovered in all classes of jawed vertebrates, including sharks, at a similar genomic location.[13][14]In fish, IL-2 shares a single receptor alpha chain with its related cytokines IL-15 andIL-15-like(IL-15L).[15]This "IL-15Rα" receptor chain is similar to mammalian IL-15Rα,[16]and in tetrapod evolution a duplication of its coding gene plus further diversification created mammalian IL-2Rα.[17][18]Sequences, and structural analysis of grass carp IL-2, suggest that fish IL-2 binds IL-15Rα in a manner reminiscent of how mammalian IL-15 binds to IL-15Rα.[18][19]

Despite fish IL-2 and IL-15 sharing the same IL-15Rα chain, the stability of fish IL-2 is independent of it whereas IL-15 and especially IL-15L depend on binding to (co-presentation with) IL-15Rα for their stability and function.[15]This suggests that, like in mammals, fish IL-2, in contrast to fish IL-15 and IL-15L, is not relying on "in trans" presentation by its receptor alpha chain. As a free cytokine, mammalian IL-2 that is secreted by activated T cells is important for a negative feedback loop by the stimulation of regulatory T cells, the latter being the cells with the highest constitutive IL-2Rα (aka CD25) expression.[20][21]Besides thisnegative feedbackloop, mammalian IL-2 also participates in a positive feedback loop because activated T cells enhance their own IL-2Rα expression.[20][21]As in mammals, fish IL-2 also stimulates T cell proliferation[22]and appears to preferentially stimulate regulatory T cells.[23]Fish IL-2 induces the expression of cytokines of both type 1 (Th1) and type 2 (Th2) immunity.[15][24]

As has been found in some studies on mammalian IL-2,[25]data suggest that fish IL-2 can form homodimers and that this is an ancient property of the IL-2/15/15L-family cytokines.[15]

Homologues of IL-2 have not been reported for jawless fish (hagfish and lamprey) or invertebrates.

Role in disease

edit

While the causes ofitchinessare poorly understood, some evidence indicates that IL-2 is involved in itchypsoriasis.[26]

Medical use

edit
Aldesleukin
Clinical data
Trade namesProleukin
AHFS/Drugs.comMonograph
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChemSID
DrugBank
UNII
ChEMBL

Pharmaceutical analogues

edit

Aldesleukinis a form of recombinant interleukin-2. It is manufactured usingrecombinant DNAtechnology and is marketed as aprotein therapeuticand branded as Proleukin. It has been approved by theFood and Drug Administration(FDA) with ablack box warningand in several European countries for the treatment of cancers (malignant melanoma,renal cell cancer) in large intermittent doses and has been extensively used in continuous doses.[27][28][29]

Interking is a recombinant IL-2 with aserineat residue 125, sold by Shenzhen Neptunus.[30]

Neoleukin 2/15 is a computationally designed mimic of IL-2 that was designed to avoid common side effects.[31]However, clinical trials into this candidate were discontinued.[32]

Dosage

edit

Various dosages of IL-2 across theUnited Statesand across the world are used. The efficacy andside effectsof different dosages is often a point of disagreement.

The commercial interest in local IL-2 therapy has been very low. Because only a very low dose IL-2 is used, treatment of a patient would cost about $500 commercial value of the patented IL-2. The commercial return on investment is too low to stimulate additional clinical studies for the registration of intratumoral IL-2 therapy.

United States
edit

Usually, in the U.S., the higher dosage option is used, affected by cancer type, response to treatment and general patient health. Patients are typically treated for five consecutive days, three times a day, for fifteen minutes. The following approximately 10 days help the patient to recover between treatments. IL-2 is delivered intravenously on an inpatient basis to enable proper monitoring of side effects.[33]

A lower dose regimen involves injection of IL-2 under the skin typically on an outpatient basis. It may alternatively be given on an inpatient basis over 1–3 days, similar to and often including the delivery ofchemotherapy.[33]

Intralesional IL-2 is commonly used to treat in-transit melanoma metastases and has a high complete response rate.[34]

Local application

edit

In preclinical and early clinical studies, local application of IL-2 in the tumor has been shown to be clinically more effective in anticancer therapy than systemic IL-2 therapy, over a broad range of doses, without serious side effects.[35]

Tumour blood vessels are more vulnerable than normal blood vessels to the actions of IL-2. When injected inside a tumor, i.e. local application, a process mechanistically similar to the vascular leakage syndrome, occurs in tumor tissue only. Disruption of the blood flow inside of the tumor effectively destroys tumor tissue.[36]

In local application, the systemic dose of IL-2 is too low to cause side effects, since the total dose is about 100 to 1000 fold lower. Clinical studies showed painful injections at the site of radiation as the most important side effect, reported by patients. In the case of irradiation of nasopharyngeal carcinoma the five-year disease-free survival increased from 8% to 63% by local IL-2 therapy[37]

Toxicity

edit

Systemic IL-2 has a narrowtherapeutic window,and the level of dosing usually determines the severity of the side effects.[38]In the case of local IL-2 application, the therapeutic window spans several orders of magnitude.[35]

Some common side effects:[33]

More serious and dangerous side effects sometimes are seen, such asbreathingproblems, seriousinfections,seizures,allergic reactions,heartproblems,kidney failureor a variety of other possible complications.[33]The most common adverse effect of high-dose IL-2 therapy is vascular leak syndrome (VLS; also termedcapillary leak syndrome). It is caused by lung endothelial cells expressing high-affinity IL-2R. These cells, as a result of IL-2 binding, causes increased vascular permeability. Thus, intravascular fluid extravasate into organs, predominantly lungs, which leads to life-threatening pulmonary or brain oedema.[39]

Other drawbacks of IL-2 cancer immunotherapy are its short half-life in circulation and its ability to predominantly expand regulatory T cells at high doses.[5][6]

Intralesional IL-2 used to treat in-transit melanoma metastases is generally well tolerated.[34]This is also the case for intralesional IL-2 in other forms of cancer, like nasopharyngeal carcinoma.[37]

Pharmaceutical derivative

edit

Eisaimarkets a drug calleddenileukin diftitox(trade name Ontak), which is a recombinant fusion protein of the human IL-2ligandand thediphtheria toxin.[40]This drug binds to IL-2 receptors and introduces the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas, malignant cells express the IL-2 receptor, so denileukin diftitox can kill them. In 1999 Ontak was approved by theU.S. Food and Drug Administration(FDA) for treatment ofcutaneous T cell lymphoma(CTCL).[41]

Preclinical research

edit

IL-2 does not follow the classical dose-response curve of chemotherapeutics. The immunological activity of high and low dose IL-2 show sharp contrast. This might be related to different distribution of IL-2 receptors (CD25, CD122, CD132) on different cell populations, resulting in different cells that are activated by high and low dose IL-2. In general high doses are immune suppressive, while low doses can stimulate type 1 immunity.[42]Low-dose IL-2 has been reported to reduce hepatitis C and B infection.[43]

IL-2 has been used in clinical trials for the treatment of chronic viral infections and as a booster (adjuvant) for vaccines. The use of large doses of IL-2 given every 6–8 weeks inHIVtherapy, similar to its use in cancer therapy, was found to be ineffective in preventing progression to anAIDSdiagnosis in two large clinical trials published in 2009.[44]

More recently low dose IL-2 has shown early success in modulating the immune system in disease like type 1 diabetes and vasculitis.[45]There are also promising studies looking to use low dose IL-2 in ischaemic heart disease.[46]

IL-2/anti-IL-2 mAb immune complexes (IL-2 ic)

edit

IL-2 cannot accomplish its role as a promisingimmunotherapeuticagent due to significant drawbacks which are listed above. Some of the issues can be overcome using IL-2 ic. They are composed of IL-2 and some of itsmonoclonal antibody(mAb) and can potentiate biologic activity of IL-2in vivo.The main mechanism of this phenomenonin vivois due to the prolongation of thecytokinehalf-life in circulation. Depending on the clone of IL-2 mAb, IL-2 ic can selectively stimulate either CD25high(IL-2/JES6-1 complexes), or CD122highcells (IL-2/S4B6). IL-2/S4B6 immune complexes have high stimulatory activity forNK cellsand memoryCD8+T cellsand they could thus replace the conventional IL-2 incancer immunotherapy.On the other hand, IL-2/JES6-1 highly selectively stimulateregulatory T cellsand they could be potentially useful fortransplantationsand in treatment ofautoimmune diseases.[47][5]

History

edit

According to an immunology textbook: "IL-2 is particularly important historically, as it is the first type I cytokine that was cloned, the first type I cytokine for which a receptor component was cloned, and was the first short-chain type I cytokine whose receptor structure was solved. Many general principles have been derived from studies of this cytokine including its being the first cytokine demonstrated to act in a growth factor–like fashion through specific high-affinity receptors, analogous to the growth factors being studied by endocrinologists and biochemists".[48]: 712 

In the mid-1960s, studies reported "activities" in leukocyte-conditioned media that promotedlymphocyteproliferation.[49]: 16 In the mid-1970s, it was discovered that T-cells could be selectively proliferated when normal humanbone marrowcells were cultured in conditioned medium obtained fromphytohemagglutinin-stimulated normal human lymphocytes.[48]: 712 The key factor was isolated from cultured mouse cells in 1979 and from cultured human cells in 1980.[50]The gene for human IL-2 was cloned in 1982 after an intense competition.[51]: 76 

Commercial activity to bring an IL-2 drug to market was intense in the 1980s and 1990s. By 1983,Cetus Corporationhad created a proprietary recombinant version of IL-2 (Aldesleukin, later branded as Proleukin), with thealanineremoved from its N-terminal and residue 125 replaced with serine.[51]: 76–77 [52]: 201 [53]Amgenlater entered the field with its own proprietary, mutated, recombinant protein and Cetus and Amgen were soon competing scientifically and in the courts; Cetus won the legal battles and forced Amgen out of the field.[51]: 151 By 1990 Cetus had gotten aldesleukin approved in nine European countries but in that year, the U.S.Food and Drug Administration(FDA) refused to approve Cetus' application to market IL-2.[29]The failure led to the collapse of Cetus, and in 1991 the company was sold toChiron Corporation.[54][55]Chiron continued the development of IL-2, which was finally approved by the FDA as Proleukin for metastaticrenal carcinomain 1992.[56]

By 1993 aldesleukin was the only approved version of IL-2, butRochewas also developing a proprietary, modified, recombinant IL-2 called teceleukin, with amethionineadded at is N-terminal, andGlaxowas developing a version called bioleukin, with a methionine added at is N-terminal and residue 125 replaced with alanine. Dozens of clinical trials had been conducted of recombinant or purified IL-2, alone, in combination with other drugs, or using cell therapies, in which cells were taken from patients, activated with IL-2, then reinfused.[53][57]Novartisacquired Chiron in 2006[58]and licensed the US aldesleukin business to Prometheus Laboratories in 2010[59]before global rights to Proleukin were subsequently acquired by Clinigen in 2018 and 2019.

References

edit
  1. ^abcGRCh38: Ensembl release 89: ENSG00000109471–Ensembl,May 2017
  2. ^abcGRCm38: Ensembl release 89: ENSMUSG00000027720–Ensembl,May 2017
  3. ^"Human PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^"Mouse PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^abcdefgArenas-Ramirez N, Woytschak J, Boyman O (December 2015)."Interleukin-2: Biology, Design and Application"(PDF).Trends in Immunology.36(12): 763–777.doi:10.1016/j.it.2015.10.003.PMID26572555.S2CID3621867.
  6. ^abcdeLiao W, Lin JX, Leonard WJ (October 2011)."IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation".Current Opinion in Immunology.23(5): 598–604.doi:10.1016/j.coi.2011.08.003.PMC3405730.PMID21889323.
  7. ^abWang X, Rickert M, Garcia KC (November 2005). "Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors".Science.310(5751): 1159–63.Bibcode:2005Sci...310.1159W.doi:10.1126/science.1117893.PMID16293754.S2CID85394260.
  8. ^Gaffen SL, Liu KD (November 2004). "Overview of interleukin-2 function, production and clinical applications".Cytokine.28(3): 109–23.doi:10.1016/j.cyto.2004.06.010.PMID15473953.
  9. ^Friedmann MC, Migone TS, Russell SM, Leonard WJ (March 1996)."Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation".Proceedings of the National Academy of Sciences of the United States of America.93(5): 2077–82.Bibcode:1996PNAS...93.2077F.doi:10.1073/pnas.93.5.2077.PMC39912.PMID8700888.
  10. ^Liao W, Lin JX, Leonard WJ (January 2013)."Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy".Immunity.38(1): 13–25.doi:10.1016/j.immuni.2013.01.004.PMC3610532.PMID23352221.
  11. ^abSpolski R, Li P, Leonard WJ (2018). "Biology and regulation of IL-2: from molecular mechanisms to human therapy".Nature Reviews Immunology.18(10): 648–659.doi:10.1038/s41577-018-0046-y.PMID30089912.S2CID51939991.
  12. ^Malek TR, Castro I (August 2010)."Interleukin-2 receptor signaling: at the interface between tolerance and immunity".Immunity.33(2): 153–65.doi:10.1016/j.immuni.2010.08.004.PMC2946796.PMID20732639.
  13. ^Bird S, Zou J, Kono T, Sakai M, Dijkstra JM, Secombes C (March 2005). "Characterisation and expression analysis of interleukin 2 (IL-2) and IL-21 homologues in the Japanese pufferfish, Fugu rubripes, following their discovery by synteny".Immunogenetics.56(12): 909–923.doi:10.1007/s00251-004-0741-7.PMID15592926.S2CID6739341.
  14. ^Dijkstra JM (February 2021). "A method for making alignments of related protein sequences that share very little similarity; shark interleukin 2 as an example".Immunogenetics.73(1): 35–51.doi:10.1007/s00251-020-01191-5.PMID33512550.S2CID231770873.
  15. ^abcdYamaguchi T, Chang CJ, Karger A, Keller M, Pfaff F, Wangkahart E, et al. (2020-10-29)."Ancient Cytokine Interleukin 15-Like (IL-15L) Induces a Type 2 Immune Response".Frontiers in Immunology.11:549319.doi:10.3389/fimmu.2020.549319.PMC7658486.PMID33193315.
  16. ^Fang W, Shao JZ, Xiang LX (July 2007). "Molecular cloning and characterization of IL-15R alpha gene in rainbow trout (Oncorhynchus mykiss)".Fish & Shellfish Immunology.23(1): 119–127.Bibcode:2007FSI....23..119F.doi:10.1016/j.fsi.2006.09.011.PMID17101279.
  17. ^Anderson DM, Kumaki S, Ahdieh M, Bertles J, Tometsko M, Loomis A, et al. (December 1995)."Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes".The Journal of Biological Chemistry.270(50): 29862–29869.doi:10.1074/jbc.270.50.29862.PMID8530383.
  18. ^abDijkstra JM, Takizawa F, Fischer U, Friedrich M, Soto-Lampe V, Lefèvre C, et al. (February 2014)."Identification of a gene for an ancient cytokine, interleukin 15-like, in mammals; interleukins 2 and 15 co-evolved with this third family member, all sharing binding motifs for IL-15Rα".Immunogenetics.66(2): 93–103.doi:10.1007/s00251-013-0747-0.PMC3894449.PMID24276591.
  19. ^Wang J, Wang W, Xu J, Jia Z, Liu Q, Zhu X, et al. (February 2021). "Structural insights into the co-evolution of IL-2 and its private receptor in fish".Developmental and Comparative Immunology.115:103895.doi:10.1016/j.dci.2020.103895.PMID33065202.S2CID223557924.
  20. ^abBusse D, de la Rosa M, Hobiger K, Thurley K, Flossdorf M, Scheffold A, et al. (February 2010)."Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments".Proceedings of the National Academy of Sciences of the United States of America.107(7): 3058–3063.Bibcode:2010PNAS..107.3058B.doi:10.1073/pnas.0812851107.PMC2840293.PMID20133667.
  21. ^abBoyman O, Sprent J (February 2012). "The role of interleukin-2 during homeostasis and activation of the immune system".Nature Reviews. Immunology.12(3): 180–190.doi:10.1038/nri3156.PMID22343569.S2CID22680847.
  22. ^Corripio-Miyar Y, Secombes CJ, Zou J (January 2012). "Long-term stimulation of trout head kidney cells with the cytokines MCSF, IL-2 and IL-6: gene expression dynamics".Fish & Shellfish Immunology.32(1): 35–44.Bibcode:2012FSI....32...35C.doi:10.1016/j.fsi.2011.10.016.PMID22051181.
  23. ^Wen Y, Fang W, Xiang LX, Pan RL, Shao JZ (August 2011)."Identification of Treg-like cells in Tetraodon: insight into the origin of regulatory T subsets during early vertebrate evolution".Cellular and Molecular Life Sciences.68(15): 2615–2626.doi:10.1007/s00018-010-0574-5.PMC11115099.PMID21063894.S2CID22936159.
  24. ^Wang T, Hu Y, Wangkahart E, Liu F, Wang A, Zahran E, et al. (2018-07-26)."Interleukin (IL)-2 Is a Key Regulator of T Helper 1 and T Helper 2 Cytokine Expression in Fish: Functional Characterization of Two DivergentIL2Paralogs in Salmonids ".Frontiers in Immunology.9:1683.doi:10.3389/fimmu.2018.01683.PMC6070626.PMID30093902.
  25. ^Fukushima K, Hara-Kuge S, Ideo H, Yamashita K (August 2001)."Carbohydrate recognition site of interleukin-2 in relation to cell proliferation".The Journal of Biological Chemistry.276(33): 31202–31208.doi:10.1074/jbc.M102789200.PMID11390392.
  26. ^Reich A, Szepietowski JC (2007)."Mediators of pruritus in psoriasis".Mediators of Inflammation.2007:1–6.doi:10.1155/2007/64727.PMC2221678.PMID18288273.
  27. ^Noble S, Goa KL (May 1997). "Aldesleukin (recombinant interleukin-2)".BioDrugs.7(5): 394–422.doi:10.2165/00063030-199707050-00007.PMID18031103.S2CID34226322.
  28. ^Bhatia S, Tykodi SS, Thompson JA (May 2009)."Treatment of metastatic melanoma: an overview".Oncology.23(6): 488–96.PMC2737459.PMID19544689.
  29. ^abPollack A (July 31, 1990)."Cetus Drug Is Blocked By F.D.A."New York Times.This source mentions approval in 9 European countries.
  30. ^"Shenzhen Neptunus Interlng-H".Bloomberg BusinessWeek.3 March 2014. Archived fromthe originalon February 27, 2011.
  31. ^Silva DA, Yu S, Ulge UY, Spangler JB, Jude KM, Labão-Almeida C, et al. (January 2019)."De novo design of potent and selective mimics of IL-2 and IL-15".Nature.565(7738): 186–191.Bibcode:2019Natur.565..186S.doi:10.1038/s41586-018-0830-7.PMC6521699.PMID30626941.
  32. ^Scott R (November 15, 2022)."Neoleukin Drops de Novo Protein Therapeutic, Slashes Workforce - Updated".BioSpace.RetrievedFebruary 1,2023.
  33. ^abcdAmerican Cancer Society.Interleukin-2 (Aldesleukin)Archived2015-02-12 at theWayback Machine.Date accessed: 07 Nov 10.
  34. ^abShi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, et al. (October 2015)."100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series".Journal of the American Academy of Dermatology.73(4): 645–54.doi:10.1016/j.jaad.2015.06.060.PMID26259990.
  35. ^abDen Otter W, Jacobs JJ, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, et al. (July 2008)."Local therapy of cancer with free IL-2".Cancer Immunology, Immunotherapy.57(7): 931–50.doi:10.1007/s00262-008-0455-z.PMC2335290.PMID18256831.
  36. ^Jacobs JJ, Sparendam D, Den Otter W (July 2005)."Local interleukin 2 therapy is most effective against cancer when injected intratumourally".Cancer Immunology, Immunotherapy.57(7): 931–50.doi:10.1007/s00262-004-0627-4.PMC11033014.PMID15685449.S2CID41522233.
  37. ^abJacobs JJ, Hordijk GJ, Jürgenliemk-Schulz IM, Terhaard CH, Koten JW, Battermann JJ, et al. (August 2005)."Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2".Cancer Immunol Immunother.57(8): 792–8.doi:10.1007/s00262-004-0627-4.PMC11033014.PMID15685449.S2CID41522233.
  38. ^Shaker MA, Younes HM (July 2009). "Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy".Journal of Pharmaceutical Sciences.98(7): 2268–98.doi:10.1002/jps.21596.PMID19009549.
  39. ^"Correction for Krieg et al., Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells".Proceedings of the National Academy of Sciences.109(1): 345. 2011-12-28.doi:10.1073/pnas.1119897109.ISSN0027-8424.PMC3252892.
  40. ^Figgitt DP, Lamb HM, Goa KL (2000). "Denileukin diftitox".American Journal of Clinical Dermatology.1(1): 67–72, discussion 73.doi:10.2165/00128071-200001010-00008.PMID11702307.S2CID195358361.
  41. ^"Changes in the Ontak (denileukin diftitiox)".Package Insert to Include a Description of Ophthalmologic Adverse Events.FDA. May 11, 2009.
  42. ^Tomova R, Pomakov J, Jacobs JJ, Adjarov D, Popova S, Altankova I, et al. (May–June 2006). "Changes in cytokine profile during local IL-2 therapy in cancer patients".Anticancer Research.26(3A): 2037–47.PMID16827142.
  43. ^Tomova R, Antonov K, Ivanova A, Jacobs JJ, Koten JW, Den Otter W, et al. (December 2009). "CLow-dose IL-2 therapy reduces HCV RNA and HBV DNA: case report".Anticancer Research.29(12): 5241–4.PMID20044643.
  44. ^"IL-2 Immunotherapy Fails to Benefit HIV-Infected Individuals Already Taking Antiretrovirals".News Release.National Institutes of Health (NIH). February 10, 2009.
  45. ^Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, et al. (December 2013). "Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial".The Lancet. Diabetes & Endocrinology.1(4): 295–305.doi:10.1016/S2213-8587(13)70113-X.PMID24622415.
  46. ^Clinical trial numberNCT03113773for "Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes (LILACS)" atClinicalTrials.gov
  47. ^Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J (March 2006)."Selective stimulation of T cell subsets with antibody-cytokine immune complexes".Science.311(5769): 1924–7.Bibcode:2006Sci...311.1924B.doi:10.1126/science.1122927.PMID16484453.S2CID42880544.
  48. ^abPaul WE (2008).Fundamental immunology(6th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins.ISBN978-0-7817-6519-0.
  49. ^Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, et al. (December 2009). "Pharmacologic administration of interleukin-2".Annals of the New York Academy of Sciences.1182(1): 14–27.Bibcode:2009NYASA1182...14C.doi:10.1111/j.1749-6632.2009.05160.x.PMID20074271.S2CID1100312.
  50. ^Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MA (August 1982)."Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity".The Journal of Experimental Medicine.156(2): 454–64.doi:10.1084/jem.156.2.454.PMC2186775.PMID6980256.
  51. ^abcRabinow P (1997).Making PCR: A story of biotechnology(Paperback ed.). Chicago, IL, USA: University of Chicago Press.ISBN978-0226701479.
  52. ^Almeida H (April–June 2011)."Drugs obtained by biotechnology processing"(PDF).Brazilian Journal of Pharmaceutical Sciences.47(2): 199–207.doi:10.1590/s1984-82502011000200002.
  53. ^abWhittington R, Faulds D (September 1993). "Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer".Drugs.46(3): 446–514.doi:10.2165/00003495-199346030-00009.PMID7693434.S2CID209143485.
  54. ^Pollack A (July 23, 1991)."2 Biotech Pioneers To Merge".New York Times.
  55. ^Lehrman S (January 20, 1992)."Cetus: A Collision Course With Failure".The Scientist Magazine.
  56. ^Dutcher JP (November 2002). "Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma".Oncology.16(11 Suppl 13): 4–10.PMID12469934.
  57. ^"D02749 (Teceleukin)".KEGG drug.
  58. ^"Chiron shareholders approve Novartis deal".SWI swissinfo.ch.Apr 19, 2006.
  59. ^"Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal".Pharmaletter.January 27, 2010.
edit
Wikimedia Commons has media related toInterleukin-2.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Interleukin_2&oldid=1245834337"